Business · 17/03/2003Updated: 10/17/2026 · 1 min read
FDA Amends Patent Extension Review Period for VITREON
Summary
The FDA is revising its regulatory review period for VITREON patent extension after agreeing with the applicant's request for revision, following a December 1998 Federal Register notice.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →